Bisphosphonates in the Prevention of Post-Traumatic Osteoarthritis
Technical Report,01 Jul 2015,30 Jun 2016
University of Delaware Newark United States
Pagination or Media Count:
The following accomplishments with regard to the Aim 2 tasks partnering-PI C. Prices responsibility for grantPR120788P1 during the reporting period from 08012015 to 07302016 are noted. The animal surgery model DMM and drug-delivery methodology intra-articular injection, which constitute the majority of the proposed research in Aim 2 have completed. The entire cohorts of the Baseline, Age-Matched, SHAM controls, DMM Surgery and DMM i.a. zoledronic acid ZA groups have been collected and analyzed by histology and u-CT analysis. Through the study of this pre-clinical mouse injury model we have established that changes in joint health, including cartilage composition and structure, and joint morphology appear very quickly following injury and are driven by very focal changes in chondrocyte health. In our animal model these changes are seen as early as 3-days post-injury and it is not unreasonable to assume that similar early changes are occurring clinically in human patient that have experienced traumatic joint injury. We have also demonstrated that while a single i.a. injection of ZA post-injury does not provide anti-osteoarthritic benefits in the mouse DMM-model of PTOA, multiple injections4 over the course of 21-days does provide a degree of protection against cartilage damage. These findings establish a framework to investigate the in vivo mechanisms underlying the efficacy of i.a. ZA in treating PTOA, and demonstrate the promise that i.a. ZA holds for the clinical translation of i.a. ZA in treating PTOA following joint injury.
- Medicine and Medical Research
- Weapons Effects (Biological)